<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423564</url>
  </required_header>
  <id_info>
    <org_study_id>14PCHN</org_study_id>
    <nct_id>NCT02423564</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Parallel Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Institute of Probiotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will evaluate the effect of Digesta-Lac in adults with occasional
      constipation in a single-center, randomized, double-blind, placebo-controlled, parallel group
      2-arm study for 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 12, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference (probiotic - placebo) in the number of weekly complete spontaneous bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The between group difference in the average number of weekly complete spontaneous bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of responders vs. non- responders for the average number of weekly complete spontaneous bowel movements</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean difference (probiotic - placebo) in the number of weekly spontaneous bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between group difference in the average number of weekly spontaneous bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of responders vs. non- responders for the average number of weekly spontaneous bowel movements</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean difference (probiotic - placebo) in the number of weekly bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between group difference in the average number of weekly bowel movements</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of responders vs. non- responders for the average number of weekly bowel movements</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bowel habits (straining, feeling of complete evacuation) as assessed by the daily bowel habits diary</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bristol Stool Score</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms related to constipation determined by the Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of the Product Perception Questionnaire</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between group difference in the percentage of subjects that used a laxative</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The between group difference in the total number of days per subject that a laxative</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory parameters of safety - CBC</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory parameters of safety - Electrolytes</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory parameters of safety - Kidney function markers</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory parameters of safety - Liver function markers</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometric measures - Weight</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometric measures - BMI</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometric measures - Blood Pressure</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometric measures - Heart Rate</measure>
    <time_frame>Screening to Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Baseline to Day 21</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Occasional Constipation</condition>
  <arm_group>
    <arm_group_label>Healthy Population with Digesta Lac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Population with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Digesta Lac</intervention_name>
    <arm_group_label>Healthy Population with Digesta Lac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Healthy Population with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18-65 years of age (inclusive)

          -  If female, subject is not of child bearing potential. Defined as females who have had
             a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal
             (natural or surgically with &gt; 1 year since last menstruation).

        OR Female subject of childbearing potential must agree to use a medically approved method
        of birth control and have a negative urine pregnancy test result. Acceptable methods of
        birth control include: Double barrier method, Hormonal contraceptives (including oral
        contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring
        (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant
        System)), Intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle

          -  BMI 18.5-35.0kg/m2

          -  Subjects must have &lt; 3 bowel movements per week for at least 2 weeks (but for not more
             than 12 weeks in the past 6 months) prior to randomization (confirmed at screening and
             baseline) and the presence of at least one other bowel symptom of constipation in at
             least 25% of defecations; Hard stools. or complete lack of loose or watery stools,
             straining during defecation, feelings of incomplete evacuation, abdominal discomfort,
             bloating/distension

          -  Healthy as determined by laboratory results, medical history and physical exam

          -  Subjects must agree not to use any other products or therapies (i.e. enemas) to treat
             their constipation during the run-in to the study (7 days prior to baseline) or during
             the course of the study except as a rescue medication.

          -  Agrees not to change current dietary habits (with the exception of avoiding pro- and
             prebiotics), smoking habits and activity/training levels one week prior to
             randomization and during the course of the study

          -  Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial

          -  Subjects currently under a doctor's care and treatment for constipation

          -  Subjects that have a history of chronic constipation(defined as &lt;3 bowel movements per
             week for more than 3 months) due to any underlying cause (IBS, functional constipation
             [chronic constipation], IBD, ulcer, etc.) based on self-report, physical examination,
             or documented medical history

          -  Subjects who have severe abdominal pain as the predominant constipation symptom as
             determined by the Principal Investigator.

          -  Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal
             fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele,
             colostomy, IBS, Crohn's disease, episiotomy or hemorrhoids.

          -  Subjects with a history of spinal injuries and/or surgeries which could result in an
             atonic colon or saddle anesthesia (i.e. spinal fusion in the lumbar spine)

          -  Subjects who have been hospitalized within the past 3 months

          -  Subjects with known renal or hepatic insufficiency

          -  Subjects with gastrointestinal bleeding or acute infection

          -  Subjects who use prescription medication to treat constipation

          -  Subjects who have previously suffered from slipped discs

          -  Subjects who plan to use OTC laxatives or stool softeners, or any other products meant
             to treat constipation other than the study supplements, during the treatment period
             (use as a rescue medication is permitted) or other therapies such as enemas.

          -  Subjects currently taking or taken within 28 days of randomization a concomitant
             medication that causes constipation which in the Principle Investigator's opinion may
             impact the study results.

          -  Any non-gastrointestinal disease/complication that, in the investigator's opinion, may
             affect subject safety or confound the evaluation of the study endpoints

          -  Immunodeficiency (i.e. HIV positive, rheumatoid arthritis, history of organ
             transplant)

          -  Clinically significant abnormal laboratory results at screening (e.g. AST and/or ALT &gt;
             2 x ULN, and/or bilirubin &gt; 2 x ULN; serum creatinine &gt; 1.5 x ULN; hemoglobin &lt; 140
             g/L for males and &lt; 123 g/L for females)

          -  Abdominal or perineal surgery within 6 months of randomization

          -  Subjects who plan on engaging in anal intercourse during the run-in or treatment
             periods of the trial. Enemas are not allowed within 7 days of randomization or
             throughout the trial.

          -  Participation in a clinical research trial within 30 days prior to randomization or
             participation in a clinical trial researching a probiotic within 60 days prior to
             randomization

          -  Currently taking anti-psychotic medication

          -  Allergy or sensitivity to study supplement ingredients

          -  Use of pre- and probiotics within 8 weeks prior to randomization

          -  Alcohol abuse (&gt;2 standard alcoholic drinks per day) or drug abuse within the past 6
             months

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent.

          -  Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures or which may pose significant
             risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Digesta-Lac</keyword>
  <keyword>Occasional Constipation</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

